Erlotinib

Grey

Brand Name(s):Tarceva

Indication:Non-small-cell lung cancer (Maintainance)

Rationale:1

Considered:Jan-07

Review Date:Feb-21

Comments:
Drug Safety Update/Roche Feb 2016

NICE TA258 June 2012
NICE TA227 June 2011

Risks of incorrect dosing of oral anti-cancer medicines – NPSA January 2008